GlaxoSmithKline (GSK) has announced positive results from a Phase 2 trial for its mRNA seasonal influenza vaccine program. The trial showed strong immune responses against influenza A and B strains in both older and younger adults, paving the way for further development.
Moderna’s new manufacturing facility in Laval, Quebec, has secured a Drug Establishment License from Health Canada, marking a significant step towards the company’s goal of producing mRNA vaccines within Canada. The site will begin manufacturing a range of respiratory vaccines, including COVID-19, RSV, and influenza, beginning in 2025.
The global mRNA vaccine market is projected to experience a decline in growth, but emerging innovations and increased demand for pandemic preparedness are driving future market trends.
Moderna’s mRNA-1769 vaccine demonstrated superior protection against mpox in monkeys compared to the currently available Jynneos vaccine, offering hope for a more effective vaccine against this emerging disease.
For the first time, scientists have tested an mRNA vaccine in a patient with glioblastoma, an aggressive type of brain cancer. The vaccine triggered a strong immune response, offering hope for a new treatment approach. The vaccine was created by extracting genetic material from the patient’s tumor and replicating it to make mRNA, which then instructed the body to attack the cancer cells.
